<DOC>
	<DOCNO>NCT01470989</DOCNO>
	<brief_summary>This 18-month , multi-center , open-label , clinical extension study . Patients complete earlier second extension study ( CACZ885H2356E2 CACZ885H2357E2 ) continue treat combined extension 3 study new gouty arthritis flare demand one subcutaneous ( s.c. ) injection canakinumab 150 mg .</brief_summary>
	<brief_title>Î²-RELIEVED - REsponse Acute fLare In prEVEntion episoDes Re-flare Gout - Extension 3 ( E3 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Gouty</mesh_term>
	<criteria>Patients complete second extension study CACZ885H2356E2 CACZ885H2357E2 Patients treat canakinumab core study subsequent extension Pregnant nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>gouty arthritis</keyword>
</DOC>